Mechlorethamine
- Generic Name
- Mechlorethamine
- Brand Names
- Valchlor, Ledaga
- Drug Type
- Small Molecule
- Chemical Formula
- C5H11Cl2N
- CAS Number
- 51-75-2
- Unique Ingredient Identifier
- 50D9XSG0VR
- Background
A vesicant and necrotizing irritant destructive to mucous membranes, mechlorethamine is an alkylating drug. It was formerly used as a war gas. The hydrochloride is used as an antineoplastic in Hodgkin's disease and lymphomas. It causes severe gastrointestinal and bone marrow damage.
...
- Indication
For the palliative treatment of Hodgkin's disease (Stages III and IV), lymphosarcoma, chronic myelocytic or chronic lymphocytic leukemia, polycythemia vera, mycosis fungoides, and bronchogenic carcinoma. Also for the palliative treatment of metastatic carcinoma resulting in effusion.
- Associated Conditions
- Bronchogenic Carcinoma, Chronic Lymphocytic Leukemia, Hodgkins Disease (HD), Lymphoma, Diffuse, Mycosis Fungoides (MF), Polycythemia Vera (PV), Stage I Mycosis Fungoides, Malignant effusion
- Associated Therapies
- -
Phase 3 FLASH2 Trial of HyBryte in CTCL Underway
Soligenix initiated Phase 3 FLASH2 trial of HyBryte in CTCL, with extended treatment period. HyBryte showed continued improvement post-treatment in a comparator trial. Phase 2 trial of SGX945 for Behcet’s disease also initiated. Valuation remains at $35 per share.
HyBryte™ Clinical Results Demonstrate Continued Improvement Post-Treatment
Soligenix announces continued improvement in HyBryte™-treated patients and lesions post-treatment, with statistically significant efficacy against plaque lesions compared to Valchlor®, and no safety concerns raised.
Phase 3 CTCL Trial to Initiate Before End of 2024
Soligenix (NASDAQ:SNGX) plans to start a Phase 3 trial of HyBryte for CTCL by end of 2024, with expected results in H2 2026. Recent supportive trials showed HyBryte's efficacy and safety. A partnership with Sterling Pharma aims to scale hypericin production. Q3 2024 financials showed no revenue, with R&D expenses up due to new trials. Soligenix holds $9.8M in cash and expects data from ongoing trials in 2025.
HyBryte™ Expanded Treatment Results to be Presented at the European Organisation for ...
Soligenix presents HyBryte™ therapy findings at EORTC meeting, showing improved response rates with extended treatment and increased light doses in cutaneous T-cell lymphoma (CTCL).
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath